← Back to Search

Radiation

Definitive locoregional treatment for Cancer

Phase 2
Waitlist Available
Led By Dennise Carter, MD
Research Sponsored by Rocky Mountain Cancer Centers
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Summary

Patients with metastatic cancer are usually treated with systemic therapy (treating the entire body) with the assumption that any localized treatment of clinically apparent metastases would not impact survival. In the setting of increasingly effective systemic therapy and limited metastatic disease, aggressive treatment to clinically active sites of disease (alone or in addition to systemic therapy) may improve survival.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Survival
Secondary study objectives
Locoregional disease control
Progression free survival (PFS)
Toxicity

Trial Design

1Treatment groups
Experimental Treatment
Group I: Definitive locoregional treatmentExperimental Treatment5 Interventions
All sites of active disease should be treated definitively (with one of the interventions listed below). Definitive treatment does not have to be the same for all sites of disease.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Radioembolization
2020
Completed Phase 2
~30
Stereotactic Radiosurgery
2021
Completed Phase 2
~440

Find a Location

Who is running the clinical trial?

Rocky Mountain Cancer CentersLead Sponsor
7 Previous Clinical Trials
1,399 Total Patients Enrolled
Dennise Carter, MDPrincipal InvestigatorRocky Mountain Cancer Centers
~6 spots leftby Sep 2025